Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
Anti-Her2 II / Anti-Her2 IV Bi-specific antibody ADC | Bioconjugates | Oncology/Cancer | Solid tumor | Preclinical | Global |
Her2xCD3 BsAb | Bispecific antibody | Oncology/Cancer | HER2-positive Cancer | Phase I | Global |
5e5 of anti-Her2 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human Her2, His Tag (Cat. No. HE2-HA2H9) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). APC signal was used to evaluate the binding activity (QC tested).
Herceptin captured on Protein A Chip can bind Biotinylated Human Her2, His, Avitag, premium grade (Cat. No. HE2-H82E2) with an affinity constant of 30.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Trastuzumab biosimilar (AryoGen Pharmed) | Approved | Aryogen Biopharma | AryoTrust | Stomach Neoplasms; Breast Neoplasms | Details | |||||
Trastuzumab/Hyaluronidase | Approved | Genentech Inc | Herceptin Hylecta | United States | Breast Neoplasms | Genentech Inc | 2019-02-28 | Breast Neoplasms | Details | |
Trastuzumab biosimilar (Dr. Reddy's Laboratories) | Approved | Dr Reddy's Laboratories Ltd | Hervycta | India | Breast Neoplasms | Dr Reddy's Laboratories Ltd | 2018-07-26 | Breast Neoplasms | Details | |
Trastuzumab biosimilar (Intas Pharmaceuticals) | Approved | Intas Biopharmaceuticals | Breast Neoplasms | Details | ||||||
Trastuzumab biosimilar (AXXO) | Approved | Axxo | Breast Neoplasms | Details | ||||||
Trastuzumab biosimilar (Reliance Life Sciences) | R-TPR-016 | Approved | Reliance Life Sciences | TrastuRel | India | Breast Neoplasms | Reliance Life Sciences | 2015-01-01 | Breast Neoplasms | Details |
Trastuzumab biosimilar (Zydus) | Approved | Zydus Cadila | Vivitra | India | Breast Neoplasms | Zydus Cadila | 2016-01-01 | Breast Neoplasms | Details | |
Trastuzumab biosimilar (Biocad) | BCD-022 | Approved | Biocad | HERtiCAD | Russian Federation | Breast Neoplasms | Biocad | 2016-01-01 | Breast Neoplasms | Details |
Trastuzumab emtansine biosimilar (Zydus Cadila) | ZRC-3256 | Approved | Zydus Cadila | Ujvira | India | Breast Neoplasms | Zydus Cadila | 2021-05-24 | Breast Neoplasms | Details |
Trastuzumab/Pertuzumab | RO-7198574; RG-6264 | Approved | F. Hoffmann-La Roche Ltd | Phesgo | EU | Breast Neoplasms | Roche Registration Gmbh | 2020-06-29 | Breast Neoplasms; Metastatic breast cancer | Details |
Trastuzumab biosimilar (Shanghai Henlius Biotech) | HLX-02 | Approved | Shanghai Henlius Biotech Co Ltd | Zercepac, 汉曲优 | Australia | Stomach Neoplasms; Breast Neoplasms | Cipla Australia Pty Ltd | 2020-07-27 | Stomach Neoplasms; Neoplasms; Breast Neoplasms | Details |
Ado-trastuzumab emtansine | RG-3502; R-3502; T-DM1; PRO-132365; RO-5304020 | Approved | Genentech Inc | Kadcyla, 赫赛莱 | Mainland China | Breast Neoplasms | Roche Pharma (Schweiz) Ag | 2013-02-22 | Solid tumours; Hematologic Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Breast Neoplasms; Cholangiocarcinoma; Urologic Neoplasms; Lung Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Tucatinib | ARRY-380; ONT-380; MK-7119 | Approved | Array Biopharma | Tukysa | EU | Breast Neoplasms | Seagen Netherlands Bv | 2020-04-17 | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Hepatic Insufficiency; Meningeal Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Neoplasm Metastasis | Details |
Disitamab Vedotin | RC-48-ADC; RC48-ADC; RC-48 | Approved | RemeGen Co Ltd | 爱地希 | Mainland China | Carcinoma, Transitional Cell | RemeGen Co Ltd | 2021-06-08 | Liver Neoplasms; Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Genital Diseases, Female; Esophageal Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Genital Neoplasms, Female; Breast Diseases; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Dacomitinib | PF-299; PF-804; PF-299804; PF-00299804; PF-00299804-3; PF-00299804-03 | Approved | Pfizer Inc | Vizimpro | Mainland China | Carcinoma, Non-Small-Cell Lung | Pfizer Europe Ma Eeig | 2018-09-27 | Colorectal Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Penile Neoplasms; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Head and Neck Neoplasms; Brain Neoplasms; Carcinoma, Large Cell; Liver Diseases; Glioblastoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Solid tumours | Details |
Pertuzumab | RG-1273; RO-4368451-F01; rhuMab-2C4; RO-4368451; R-1273 | Approved | Genentech Inc | Perjeta, Omnitarg | Mainland China | Breast Neoplasms | Roche Pharma (Schweiz) Ag | 2012-06-08 | Neuroendocrine Tumors; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Fallopian Tube Neoplasms; Multiple Endocrine Neoplasia; Carcinoma, Neuroendocrine; Peritoneal Neoplasms; Neuroblastoma; Prostatic Neoplasms; Breast Neoplasms; Adrenal Gland Neoplasms; Ovarian Neoplasms; Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Rectal Neoplasms; Carcinoid Tumor; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours | Details |
Trastuzumab biosimilar (Biocon/Mylan) | Bmab-200; Myl-1401O; HerMyl-1401O | Approved | Biocon Ltd, Mylan Nv | CANMAb, Ogivri, Zedora, Hertraz | EU | Breast Neoplasms; Stomach Neoplasms | Viatris Ltd | 2013-01-01 | Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Esophageal adenocarcinoma; Adenocarcinoma; Uterine Cervical Neoplasms | Details |
Trastuzumab biosimilar (Pfizer) | PF-5280014; PF-05280014 | Approved | Pfizer Inc | Trazimera | Japan | Breast Neoplasms; Stomach Neoplasms | Pfizer Inc | 2018-07-26 | Urinary Bladder Neoplasms; Melanoma; Uterine Cervical Neoplasms; Thyroid Neoplasms; Esophageal adenocarcinoma; Endometrial Neoplasms; Uterine Neoplasms; Lung Neoplasms; Glioma; Lymphoma; Colorectal Neoplasms; Cholangiocarcinoma; Prostatic Neoplasms; Breast Neoplasms; Liver Neoplasms; Multiple Myeloma; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Stomach Neoplasms; Solid tumours; Ovarian Neoplasms | Details |
Afatinib Dimaleate | BIBW-2992; BIBW-2992-MA2 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Gilotrif, Tomtovok, 吉泰瑞, Tovok, Giotrif | Mainland China | Carcinoma, Non-Small-Cell Lung | Boehringer Ingelheim International Gmbh | 2013-07-12 | Lymphoma; Prostatic Neoplasms; Brain Neoplasms; Urethral Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Ureteral Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Breast Neoplasms; Uterine Neoplasms; Glioma; Esophageal Squamous Cell Carcinoma; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Hematologic Neoplasms; Liver Diseases; Urinary Bladder Neoplasms; Chordoma; Multiple Myeloma; Neuroectodermal Tumors; Glioblastoma; Neoplasms; Neoplasms, Squamous Cell; Renal Insufficiency; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Rhabdomyosarcoma; Head and Neck Neoplasms; Solid tumours | Details |
Fam-trastuzumab deruxtecan | DS-8201a; DS-8201 | Approved | Daiichi Sankyo Co Ltd | Enhertu | United States | Carcinoma, Non-Small-Cell Lung | Daiichi Sankyo Co Ltd | 2019-12-20 | Osteosarcoma; Uterine Cervical Neoplasms; Neoplasm Metastasis; Gastrointestinal Neoplasms; Adenocarcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Brain metastases; Metastatic breast cancer; Meningeal Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Neoplasms; Neoplasms, Glandular and Epithelial; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours; Biliary Tract Neoplasms | Details |
Trastuzumab | R-597; RO45-2317; Anti-HER2/neu-MAb; huMAb4D5-8; RG-597; MKC-454 | Approved | Genentech Inc | Herceptin, 赫赛汀 | Mainland China | Stomach Neoplasms | Roche Pharma (Schweiz) Ag | 1998-09-25 | Sarcoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Adenocarcinoma; Lung Neoplasms; Metastatic breast cancer; Vulvar Diseases; Endometrial Neoplasms; Urologic Neoplasms; Carcinoma, Mucoepidermoid; Carcinoma, Acinar Cell; Urethral Neoplasms; Prostatic Neoplasms; Solid tumours; Breast Neoplasms; Urinary Bladder Neoplasms; Salivary Gland Neoplasms; Colonic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Stomach Neoplasms; Meningeal Carcinomatosis; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplastic Cells, Circulating; Ependymoma | Details |
Lapatinib Ditosylate Hydrate | GW-572016; GW-572016F; GW-2016 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | Tykerb, Tyverb, 泰立沙, Tykerb/Tyverb | Mainland China | Breast Neoplasms | Glaxosmithkline Ag | 2007-03-13 | Neoplasms, Gonadal Tissue; Carcinoma, Acinar Cell; Carcinoma, Mucoepidermoid; Colorectal Neoplasms; Astrocytoma; Gliosarcoma; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Lymphoma; Glioma; Brain metastases; Lung Neoplasms; Endometrial Neoplasms; Brain Neoplasms; Laryngeal Neoplasms; Gallbladder Neoplasms; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Neoplasm Metastasis; Tongue Neoplasms; Melanoma; Breast Neoplasms, Male; Carcinoma, Non-Small-Cell Lung; Neuroma, Acoustic; Pancreatic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Ependymoma; Liver Neoplasms; Medulloblastoma; Stomach Neoplasms; Esophageal Neoplasms; Abdominal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma; Carcinoma, Ovarian Epithelial; Solid tumours; Carcinoma, Verrucous; Glioblastoma; Salivary Gland Neoplasms; Neoplasms; Neurofibromatosis 2; Urinary Bladder Neoplasms; Carcinoma, Adenoid Cystic; Central Nervous System Neoplasms; Oligodendroglioma; Breast Neoplasms; Prost | Details |
Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Pharmaceutical Co Ltd | 泰瑞沙, Tagrisso | Mainland China | Carcinoma, Non-Small-Cell Lung | Astrazeneca Ab | 2015-11-13 | Uterine Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Brain metastases; Esophageal adenocarcinoma; Cholangiocarcinoma; Lymphoma; Glioma; Endometrial Neoplasms; Thyroid Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma of Lung; Liver Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Skin Neoplasms; Colonic Neoplasms; Glioblastoma; Multiple Myeloma; Urinary Bladder Neoplasms | Details |
Pyrotinib Maleate | HTI-1001; SHR-1258; BLTN | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妮 | Mainland China | Breast Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2018-08-12 | Solid tumours; Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma of Lung; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms | Details |
Neratinib Maleate | CAN-030; HKI-272; PF-0528767; WAY-179272; PB-272 | Approved | Pfizer Pharmaceuticals Ltd (China) | Nerlynx, 贺俪安 | Mainland China | Breast Neoplasms | Excella Gmbh & Co Kg | 2017-07-17 | Solid tumours; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Brain metastases; Carcinoma, Non-Small-Cell Lung | Details |
Inetetamab | CMAB-302 | Approved | Shanghai Cp Guojian Pharmaceutical Co Ltd | Cipterbin, 赛普汀 | Mainland China | Breast Neoplasms | Shanghai Cp Guojian Pharmaceutical Co Ltd | 2020-06-17 | Breast Neoplasms | Details |
Margetuximab | MGAH-22 | Approved | Macrogenics Inc | Margenza | United States | Breast Neoplasms | Macrogenics Inc | 2020-12-16 | Ovarian Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Trastuzumab biosimilar (Samsung Bioepis) | SB-3; AMT-901 | Approved | Samsung Bioepis Co Ltd | Samfenet, Ontruzant | United States | Breast Neoplasms; Stomach Neoplasms | Samsung Bioepis Co Ltd | 2017-11-15 | Stomach Neoplasms; Breast Neoplasms | Details |
Trastuzumab biosimilar (Synthon) | ABP-980 | Approved | Synthon Bv | Kanjinti | United States | Breast Neoplasms; Stomach Neoplasms | Amgen Inc | 2018-05-16 | Breast Neoplasms; Uterine Cervical Neoplasms; Adenocarcinoma; Melanoma; Endometrial Neoplasms; Esophageal adenocarcinoma; Uterine Neoplasms; Lung Neoplasms; Thyroid Neoplasms; Glioma; Lymphoma; Colorectal Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Carcinoma, Intraductal, Noninfiltrating; Ovarian Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Colonic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Carcinoma, Renal Cell; Solid tumours; Liver Neoplasms | Details |
Trastuzumab biosimilar (Celltrion) | CT-P6; CT-P06 | Approved | Celltrion Inc | Herzuma | United States | Breast Neoplasms | Celltrion Inc | 2014-01-01 | Stomach Neoplasms; Breast Neoplasms | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Recombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) | Phase 1 Clinical | Shenzhen Main Luck Pharmaceuticals Inc | Breast Neoplasms | Details | |
Pertuzumab biosimilar (CTTQ) | TQB-2440 | Phase 3 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Breast Neoplasms | Details |
Recombinant humanized anti-HER2 antibody (Hisun Pharma) | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Breast Neoplasms | Details | |
JRF-103 | JRF103; JRF-103 | Phase 2 Clinical | Shenzhen Jinrui Foundation Biotechnology Co Ltd | Solid tumours | Details |
Trastuzumab biosimilar(Aprogen/Nichi-Iko) | AP-06 | Phase 3 Clinical | Nichi-Iko Pharmaceutical Co Ltd, Aprogen | Breast Neoplasms | Details |
Anti-HER2 CAR T-cell therapy (Baylor College of Medicine/The Hospital for Sick Children/Texas Children's Hospital/The Methodist Hospital System ) | Phase 1 Clinical | Baylor College Of Medicine, The Hospital For Sick Children, Texas Children'S Hospital, The Methodist Hosp Research Institute | Sarcoma | Details | |
SSGJ-706 | SSGJ-706 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours; Lymphoma | Details |
PM-3002 | PM-3002 | Phase 1 Clinical | Biotheus Inc | Details | |
99mTc- ADAPT6 | 99mTc- ADAPT6; ADAPT6; SNA-018 | Phase 1 Clinical | Uppsala University, Kth Royal Institute Of Technology | Breast Neoplasms | Details |
BAY-2701439 | BAY-2701439 | Phase 1 Clinical | Bayer AG | Neoplasms | Details |
TAA-013 | TAA-013 | Phase 3 Clinical | Tot Biopharm Co Ltd | Breast Neoplasms | Details |
HL-02 | HL-02 | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Breast Neoplasms | Details |
TGFBeta-resistant-HER2-EBV-CTLs | TGFBeta-resistant-HER2-EBV-CTLs | Phase 1 Clinical | Baylor College Of Medicine | Neoplasms | Details |
Trastuzumab biosimilar (United BioPharma) | UB-921 | Phase 1 Clinical | United Biopharma Inc | Breast Neoplasms | Details |
IBPM002BZ (Inbiopro Solutions) | IBPM-002BZ | Clinical | Inbiopro Solutions | Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms | Details |
Trastuzumab biosimilar (Hualan Biological Engineering) | Phase 1 Clinical | Hualan Genetic Engineering Co Ltd | Stomach Neoplasms; Breast Neoplasms | Details | |
IBPM003TZ (Inbiopro Solutions) | IBPM-003TZ | Clinical | Inbiopro Solutions | Breast Neoplasms | Details |
PB-357 | PB-357 | Phase 1 Clinical | Pfizer Inc | Neoplasms | Details |
Anti-HER2 CAR T-cell therapy (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Research Institute | Central Nervous System Neoplasms | Details | |
KSP-QRH-E3-IRDye800 | Phase 1 Clinical | University Of Michigan | Cholangiocarcinoma | Details | |
Recombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech) | HS-630; HS630 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd | Breast Neoplasms | Details |
SHR-A1201 | SHR-A1201 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Breast Neoplasms | Details |
Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) | Phase 2 Clinical | University Of Michigan, Huazhong University Of Science And Technology, University Of Virginia Cancer Center, Medimmune | Breast Neoplasms | Details | |
AU-101 | AU-101 | Phase 2 Clinical | Aurora Biopharma | Glioblastoma; Osteosarcoma; Breast Neoplasms | Details |
68Ga-anti-HER2 nanobodies (Universite Libre de Bruxelles) | Phase 1 Clinical | Universite Libre De Bruxelles | Breast Neoplasms | Details | |
MX-402 | MX-402 | Phase 1 Clinical | Medvax Technologies | Stomach Neoplasms | Details |
Recombinant anti-HER2 subdomain II humanized monoclonal antibody(Livzon) | LZM-005 | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Breast Neoplasms | Details |
Trastuzumab biosimilar (BioXpress) | BXT-2318; BX-2318 | Clinical | Bioxpress Therapeutics Sa | Stomach Neoplasms; Metastatic breast cancer | Details |
99m-Tc labeled anti-HER2 single domain antibody (NanoMab) | 99mTc-NM-02 | Phase 1 Clinical | Nanomab Technology Ltd | Breast Neoplasms | Details |
Pertuzumab biosimilar (Xuanzhu/SL) | KM-118; KM118; XZP-KM118 | Phase 1 Clinical | Beijing Sl Pharmaceutical Co Ltd | Breast Neoplasms | Details |
SSGJ-612 | SSGJ-612 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours | Details |
Pertuzumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Breast Neoplasms | Details | |
Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
GB-251 | GB-251; NBT-828; GB221-NBT828 ADC-1 | Phase 1 Clinical | Genor Biopharma Co Ltd, Newbio Therapeutics Inc | Breast Neoplasms; Metastatic breast cancer | Details |
Puvitinib | Phase 1 Clinical | Suzhou Teligene Ltd | Solid tumours | Details | |
KY-1701 | KY-1701 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Breast Neoplasms | Details |
GB-235 | GB-235 | Phase 1 Clinical | Genor Biopharma Co Ltd | Breast Neoplasms | Details |
Pertuzumab biosimilar (Jushi Biopharmaceutical ) | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Breast Neoplasms; Metastatic breast cancer | Details | |
Epertinib | S-222611 | Phase 2 Clinical | Shionogi & Co Ltd | Neoplasms | Details |
AU-105 | AU-105 | Phase 2 Clinical | Aurora Biopharma | Glioblastoma | Details |
99mTc-DARPinG3 | 99mTc-DARPinG3; 99mTc-DARPinG-3 | Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms | Details |
I-025-A | I-025-A | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms | Details |
Trastuzumab biosimilar (Zhejiang Hisun Pharmaceutical) | HS-022 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Breast Neoplasms | Details |
HER2/neu cancer vaccine (University of Washington/Corixa/GSK) | University Of Washington | Details | |||
CP-724714 | CP-724714 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
Mubritinib | TAK-165 | Takeda Pharmaceutical Co Ltd | Details | ||
MBS-301 | MBS-301 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd | Stomach Neoplasms; Breast Neoplasms | Details |
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) | Sichuan University | Details | |||
MP-412 | AV-412; MP-412 | Mitsubishi Tanabe Pharma | Details | ||
BVAC-B vaccine (Cellid) | BVAC-B | Cellid Company | Details | ||
TAK-285 | TAK-285 | Takeda | Details | ||
BCD-147 | BCD-147 | Biocad | Details | ||
M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | M-802 | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Breast Neoplasms | Details |
Recombinant anti-HER2 humanized monoclonal antibody complex | B-002 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms | Details |
MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Molecular Partners Ag | Details | ||
Anti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma) | B-003 (Shanghai Pharma) | Phase 1 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms | Details |
MEDI-4276 | MEDI-4276 | Medimmune Llc | Details | ||
RG-6148 | RG-6148; DHES-0815A | F. Hoffmann-La Roche Ltd | Details | ||
Hemay-022 | Hemay-022 | Phase 3 Clinical | Tianjin Hemay Pharmaceutical Co Ltd, Xiajiang Hemei Pharmaceutical Co Ltd | Breast Neoplasms; Foodborne Diseases | Details |
DZD-1516 | DZD-1516 | Phase 1 Clinical | Dizal (Jiangsu) Pharmaceutical Co Ltd | Breast Neoplasms | Details |
Recombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical) | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details | |
Recombinant human ErbB3 fragment vaccine (Zensun) | rhErbB3-f | Phase 1 Clinical | Zensun (Shanghai) Sci&Tech Co Ltd | Neoplasms | Details |
Recombinant Humanized Anti-Human Epidermal Growth Factor Receptor Monoclonal Antibody and the Dolastatins Derivative DUO5 Conjugated | ZV0203; ZV203 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Zhejiang Zova Biotherapeutics Inc, Concortis Biosystems Corp | Solid tumours | Details |
Selatinib Ditosilate | QLNC-120 | Phase 2 Clinical | Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details |
Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
AMX-3009 Maleate | AMX-3009; AMX3009马来酸 | Phase 1 Clinical | Anrun Medicine Technology (Suzhou) Co Ltd | Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms | Details |
BAT-1006 | BAT-1006 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
Pertuzumab biosimilar(EirGenix) | EG-1206A; EG-1206-A | Phase 1 Clinical | Eirgenix Inc | Breast Neoplasms | Details |
BC-004 | BC-004 | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd | Solid tumours; Breast Neoplasms | Details |
Recombinant anti-HER2 humanized monoclonal antibody (Shanghai Institute of Biological Products) | SIBP-01 | Phase 3 Clinical | Shanghai Institute Of Biological Products Co Ltd | Stomach Neoplasms; Breast Neoplasms | Details |
IMM-2902 | IMM-2902 | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
Recombinant anti-HER2 subdomain II and subdomain IV humanized monoclonal antibody(Xuanzhu) | XZP-KM257; KM257/252; KM-257 | Phase 1 Clinical | Beijing Kangming Bio New Drug Development Co Ltd | Solid tumours | Details |
Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hankemab) | Phase 1 Clinical | Solid tumours | Details | ||
NIP-142 | NIP-142 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung | Details | |
trastuzumab biosimilar (Hetero) | Ado-Trastuzumab biosimilar (Hetero) | Phase 3 Clinical | Hetero Drugs Ltd | Neoplasms | Details |
Trastuzumab biosimilar (BioIntegrator) | BI-Mab-03 | Phase 1 Clinical | Biointegrator Llc | Breast Neoplasms | Details |
TT-16 | TT-16 | Phase 1 Clinical | Tessa Therapeutics Ltd | Solid tumours | Details |
Trastuzumab biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Serum Institute Of India Ltd, Neuclone | Stomach Neoplasms; Breast Neoplasms | Details | |
MB-103 | MB-103 | Phase 1 Clinical | Mustang Bio Inc, City Of Hope National Medical Center | Glioblastoma; Brain metastases | Details |
HER2(EQ)BBzeta/CD19 T cells (City of Hope) | Phase 1 Clinical | Mustang Bio Inc, City Of Hope National Medical Center | Glioma | Details | |
SPH-5030 | SPH-5030 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Solid tumours | Details |
ORIC-114 | ORIC-114 | Phase 1 Clinical | Voronoi | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
HER2 cancer vaccine (BioLife Science) | PEV-6; PEV-6A; IMU-131 | Phase 2 Clinical | Pevion Biotech Ltd | Esophageal Neoplasms; Stomach Neoplasms; Gastrointestinal Neoplasms; Adenocarcinoma | Details |
MT-5111 | MT-5111 | Phase 1 Clinical | Molecular Templates Inc | Solid tumours | Details |
BDC-1001 | BDC-1001 | Phase 2 Clinical | Bolt Biotherapeutics Inc | Solid tumours | Details |
Iodine-131-SGMIB anti-HER2 monoclonal antibody | [131I]-SGMIB Anti-HER2-VHH1; 131I-SGMIB-anti-HER2-VHH1; Iodine-131-SGMIB-anti-HER2-VHH1; CAM-H2 | Phase 2 Clinical | Camel-Ids Nv | Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms | Details |
TAC01-HER2 | TAC01-HER2 | Phase 2 Clinical | Triumvira Immunologics Inc | Solid tumours | Details |
NeuCeptin | NeuCeptin | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Stomach Neoplasms; Breast Neoplasms | Details |
Anti-CD3-anti-HER2-activated T cells | Phase 2 Clinical | Transtarget | Breast Neoplasms; Prostatic Neoplasms | Details | |
Pertuzumab biosimilar (Qilu Pharmaceutical) | QL-1209 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details |
AE-37/GP-2 vaccine | AE-37 (Generex Biotechnology Corporation) | Phase 2 Clinical | Generex Biotechnology Corp | Triple Negative Breast Neoplasms; Breast Neoplasms | Details |
HER.CAR-CMV-specific-CTLs | HER.CAR-CMV-specific-CTLs | Phase 1 Clinical | Baylor College Of Medicine | Glioblastoma | Details |
4-1BBz CD19-Her2tG (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Neoplasms; Lymphoma | Details | |
Autologous-HER2-specific-T-cells | Autologous-HER2-specific-T-cells | Phase 1 Clinical | Baylor College Of Medicine | Sarcoma; Brain Neoplasms | Details |
Multiple 4SCAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Breast Neoplasms | Details | |
Autologous AdHER2 dendritic cell vaccine (National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Neoplasms; Breast Neoplasms; Adenocarcinoma; Neoplasm Metastasis | Details | |
ALT-P7 | HM2-MMAE; ALT-P7 | Phase 1 Clinical | Alteogen Inc | Stomach Neoplasms; Breast Neoplasms | Details |
Pertuzumab biosimilar(Hisun Pharm) | HS-627; HS627 | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd | Breast Neoplasms | Details |
TPIV-100 (TapImmune) | TPIV-100 | Phase 2 Clinical | Mayo Clinic | Carcinoma, Intraductal, Noninfiltrating; Breast Neoplasms; Breast Neoplasms, Male | Details |
HER-2/Neu pulsed DC1 vaccine (University of Pennsylvania) | Phase 1 Clinical | University Of Pennsylvania, National Cancer Institute | Breast Neoplasms | Details | |
CIDeCAR | Phase 1 Clinical | Bellicum Pharmaceuticals Inc, National Cancer Institute | Osteosarcoma; Sarcoma; Neuroblastoma; Melanoma | Details | |
89Zr-ss-Pertuzumab | Phase 1 Clinical | Genentech Inc | Breast Neoplasms; Metastatic breast cancer | Details | |
HER-2 Specific CAR T Cell | Phase 1 Clinical | Pediatric Brain Tumor Consortium (Pbtc), St. Jude Children'S Research Hospital | Ependymoma | Details | |
HER2.taNK | NK-92/5.28.z | Phase 1 Clinical | Nantkwest Inc | Glioblastoma | Details |
Cinrebafusp alfa | PRS-343 | Phase 2 Clinical | Pieris Pharmaceuticals | Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms | Details |
99mTc-HPArk2 | 99mTc-HPArk2; 99-mTc-HPArk-2 | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms | Details |
Recombinant anti-HER2 antibody-Tub114 | DAC-001; DX126-262 | Phase 2 Clinical | Hangzhou Dac Biotech Company Ltd | Stomach Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
Pertuzumab biosimilar(Zydus Cadila) | ZRC-3277 | Phase 3 Clinical | Zydus Cadila | Breast Neoplasms | Details |
PLB-1004 | PLB-1004 | Phase 1 Clinical | Beijing Anshi Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
AB-201 (Artiva Biotherapeutics) | Phase 1 Clinical | Artiva Biotherapeutics Inc | Solid tumours | Details | |
ETBX-021 | ETBX-021 | Phase 2 Clinical | Nantbioscience Inc, Etubics Corp | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
CT-0508 | Phase 1 Clinical | Carisma Therapeutics Inc | Digestive System Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Endometrial Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms; Biliary Tract Neoplasms; Carcinoma, Ductal; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Inflammatory Breast Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Stomach Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours | Details | |
SSGJ-705 | SSGJ-705 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
MRG-002 | MRG-002 | Phase 2 Clinical | Shanghai Miracogen Inc | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
A-166 | A-166 | Phase 2 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Mouth Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Mucoepidermoid; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Urinary Bladder Neoplasms; Lip Neoplasms; Laryngeal Neoplasms; Tonsillar Neoplasms; Lung Neoplasms; Tongue Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Cystadenocarcinoma, Mucinous; Liver Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Skin Neoplasms; Colonic Neoplasms; Rare Diseases; Carcinoma, Transitional Cell; Neoplasms | Details |
[89Zr]-Df-Trastuzumab | Phase 1 Clinical | University Of Alabama At Birmingham | Solid tumours; Neoplasms; Breast Neoplasms | Details | |
Runimotamab | BTRC-4017A; RG-6194 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms | Details |
Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Pertuzumab biosimilar(SL Pharma/Combio) | Phase 1 Clinical | Beijing Kangming Bio New Drug Development Co Ltd, Beijing Sl Pharmaceutical Co Ltd | Inflammatory Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details | |
FDA022 Antibody Drug Conjugate | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details | |
HLX-22 | AC-101; HLX-22 | Phase 2 Clinical | Shanghai Henlius Biotech Co Ltd | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
GQ-1005 | GQ-1005; GQ1005 | Phase 1 Clinical | GeneQuantum Healthcare (Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
anti-HER2 ADC (Pfizer) | PF-06804103 | Phase 2 Clinical | Pfizer Inc | Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms | Details |
YH-32367 | ABL105; YH-32367 | Phase 2 Clinical | Abl Bio Inc | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
EX-101 | EX-101; EX101 | Phase 1 Clinical | Guangzhou ASM Biomedical Technology Co Ltd | Solid tumours | Details |
XZP-5209 | XZP-5209 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung | Details | |
Tarloxotinib Bromide | PR-610; TH-4000; SN-33999 | Phase 2 Clinical | Threshold | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
DB-1303 | DB-1303 | Phase 2 Clinical | Duality Biologics Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
JSKN-003 | JSKN-003 | Phase 1 Clinical | Alphamab Oncology | Solid tumours; Neoplasms | Details |
BB-1701 | BB-1701 | Phase 2 Clinical | Baili Sikang Biomedicine (Hangzhou) Co Ltd | Solid tumours; Carcinoma, Transitional Cell | Details |
ORM-5029 | ORM-5029 | Phase 1 Clinical | Orum Therapeutics Inc | Solid tumours; Breast Neoplasms | Details |
HER2/Neu GP2 vaccine(Greenwich LifeSciences Inc/NuGenerex Immuno Oncology) | GLSI-100 | Phase 3 Clinical | Antigen Express Inc, Norwell Inc | Breast Neoplasms | Details |
SAR-443216 | SAR-443216 | Phase 1 Clinical | Sanofi | Stomach Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
Tesevatinib | XL-647; KD-020; KD-019; EXEL-7647 | Phase 2 Clinical | Exelixis Inc | Neoplasms; Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
ZN-A-1041 | ZN-A-1041 | Phase 1 Clinical | Suzhou Zanrong Pharmaceutical Technology Co Ltd | Solid tumours; Neoplasms; Breast Neoplasms | Details |
DP-303c | DP-303c; DP303c | Phase 2 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Salivary Gland Neoplasms; Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details |
BAY-2927088 | BAY-2927088; BAY2927088 | Phase 1 Clinical | Bayer Healthcare Company Ltd, Bayer AG | Carcinoma, Non-Small-Cell Lung | Details |
AIP-303 | AIP-303 | Phase 2 Clinical | Advanced Imaging Projects | Breast Neoplasms | Details |
Larotinib Mesylate | Z-650 | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
Sunvozertinib | DZD-9008 | Phase 2 Clinical | Dizal (Jiangsu) Pharmaceutical Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung | Details |
KSP-910638-G | KSP-910638G; KSP-910638-G | Phase 1 Clinical | University Of Michigan | Gastrointestinal Neoplasms | Details |
TAS-2940 | TAS-2940 | Phase 1 Clinical | Taiho Oncology Inc | Solid tumours; Glioblastoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
99mTc-HE3-G3 | 99mTc-HE3-G3; 99-mTc-HE-3-G-3; 99m-Tc-HE-3-G-3; 99mTc-(HE)3-G3 | Phase 1 Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Solid tumours; Breast Neoplasms | Details |
99mTc-MIRC213 | 99-mTc-MIRC-213 | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms | Details |
99mTc-MIRC208 | Clinical | Beijing Cancer Hospital | Neoplasms | Details | |
Gancotamab | MM-302 | Phase 2 Clinical | Merrimack Pharmaceuticals Inc | Ovarian Neoplasms; Breast Neoplasms | Details |
FCN-411 | FCN-411 | Phase 2 Clinical | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Pirotinib Hydrochloride | KBP-5209 | Phase 2 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Solid tumours; Neoplasms; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Trastuzumab biosimilar (Alteogen) | ALT-L2; ALT-02; QL-1701; ALT-LS2 | Phase 3 Clinical | Alteogen Inc | Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms | Details |
ARV-471 | ARV-471; PF-07850327 | Phase 2 Clinical | Arvinas Inc | Breast Neoplasms | Details |
Varlitinib Ditosylate | QBT-01; ARRY-543; SPS-4370; ASLAN-001; ARRY-334543 | Phase 2 Clinical | Array Biopharma | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Bile Duct Neoplasms | Details |
SHR-A1811 | SHR-A1811 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; HR-positive breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
[18F]GE-226 | ABY-002; ABY-025; ABY-0125; 68GaABY025; GE-226; [68Ga]-ABY-025; GE-226-[18F]; [111]In-ABY-025; ABY-025-[68Ga]; ABY-025-[111In]; Gallium-68-ABY-025; Indium-111-ABY-025; Fluorine-18-GE-226 | Phase 3 Clinical | Affibody Ab | Breast Neoplasms | Details |
ACE-1702 | ACE-1702 | Phase 1 Clinical | Acepodia Taiwan Subsidiary | Solid tumours; Stomach Neoplasms; Metastatic breast cancer; Neoplasm Metastasis | Details |
GQ-1001 | GQ-1001 | Phase 2 Clinical | GeneQuantum Healthcare (Suzhou) Co Ltd | Solid tumours; Breast Neoplasms; Metastatic breast cancer | Details |
IAH-0968 | IAH-0968; IAH0968 | Phase 2 Clinical | Shenghe (China) Biopharmaceutical Co Ltd | Solid tumours; Biliary Tract Neoplasms; Colorectal Neoplasms | Details |
Pertuzumab biosimilar (Shanghai Henlius Biotech) | HLX-11 | Phase 3 Clinical | Shanghai Henlius Biotech Co Ltd | Breast Neoplasms; Metastatic breast cancer | Details |
Zanidatamab zovodotin | ZW-49 | Phase 1 Clinical | Zymeworks Inc | Neoplasms | Details |
XMT-2056 | XMT-2056 | Phase 1 Clinical | Mersana Therapeutics Inc | Stomach Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Zenocutuzumab | MCLA-128 | Phase 2 Clinical | Merus Nv | Solid tumours; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Anbenitamab | KN-026 | Phase 3 Clinical | Suzhou Alphamab Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms; Lymphoma; Gastrointestinal Neoplasms | Details |
Coprelotamab | GB-221 | Phase 3 Clinical | Genor Biopharma Co Ltd | Breast Neoplasms | Details |
Trastuzumab monomethyl auristatin F | FS-1502; LCB14-0110; LCB-14-0110 | Phase 2 Clinical | Legochembio | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Trastuzumab biosimilar (Hanwha Biologics) | HD-201 | Phase 3 Clinical | Hanwha Biologics | Kidney Neoplasms; Breast Neoplasms | Details |
Fidasimtamab | IBI-315 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
ARX-788 | ARX-788; NCB-001 | Phase 3 Clinical | Ambrx Inc | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms | Details |
Zanidatamab | ZW-25 | Phase 3 Clinical | Zymeworks Inc | Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Endometrial Neoplasms; Carcinosarcoma; Gastrointestinal Neoplasms | Details |
DF-1001 | DF-1001 | Phase 2 Clinical | Dragonfly Therapeutics Llc | Solid tumours | Details |
This web search service is supported by Google Inc.